China SXT Pharmaceuticals (SXTC) Revenue & Revenue Breakdown
China SXT Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$1.97M
Latest Revenue (Q)
$939.58K
China SXT Pharmaceuticals Revenue by Period
China SXT Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-03-31 | $1.97M | -24.23% |
| 2022-03-31 | $2.60M | -45.53% |
| 2021-03-31 | $4.78M | -7.45% |
| 2020-03-31 | $5.16M | -26.38% |
| 2019-03-31 | $7.01M | -0.10% |
| 2018-03-31 | $7.02M | 43.79% |
| 2017-03-31 | $4.88M | - |
China SXT Pharmaceuticals generated $1.97M in revenue during NA 2023, up -24.23% compared to the previous quarter, and up 28.09% compared to the same period a year ago.
China SXT Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-09-30 | $939.58K | 100.00% |
| 2023-06-30 | $469.79K | -38.46% |
| 2023-03-31 | $763.39K | 100.00% |
| 2022-12-31 | $381.70K | -68.41% |
| 2022-09-30 | $1.21M | 100.00% |
| 2022-06-30 | $604.14K | -105.25% |
| 2022-03-31 | $-11.50M | 23.32% |
| 2021-03-31 | $-9.33M | -583.20% |
| 2020-09-30 | $1.93M | -62.61% |
| 2020-03-31 | $5.16M | -26.38% |
| 2019-03-31 | $7.01M | 78.98% |
| 2018-09-30 | $3.92M | 173.45% |
| 2018-03-31 | $1.43M | -74.35% |
| 2017-12-31 | $5.59M | - |
China SXT Pharmaceuticals generated $939.58K in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up 155.52% compared to the same period a year ago.
China SXT Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTPI | Petros Pharmaceuticals | $5.82B | $1.39M |
| PROC | Procaps Group | $409.92M | $118.41M |
| ACOR | Acorda Therapeutics | $102.42M | $20.29M |
| ALIM | Alimera Sciences | $80.75M | $23.01M |
| QLI | Qilian Group | $46.47M | $17.31M |
| SBFM | Sunshine Biopharma | $39.85M | $9.30M |
| BFRI | Biofrontera | $34.01M | $7.83M |
| GHSI | Guardion Health Sciences | $12.25M | $36.35K |
| JUPW | Safety Shot | $6.20M | $910.01K |
| AKAN | Akanda | $2.16M | $762.61K |
| SXTC | China SXT Pharmaceuticals | $1.97M | $939.58K |
| LSDI | Lucy Scientific Discovery | $7.05K | $9.68K |
| SHPH | Shuttle Pharmaceuticals | - | - |
| HUGE | FSD Pharma | - | - |
| PRFX | PainReform | - | - |
| RGC | Regencell Bioscience | - | - |
SXTC Revenue FAQ
What is China SXT Pharmaceuticals’s yearly revenue?
China SXT Pharmaceuticals's yearly revenue for 2023 was $1.97M, representing a decrease of -24.23% compared to 2022. The company's yearly revenue for 2022 was $2.6M, representing a decrease of -45.53% compared to 2021. SXTC's yearly revenue for 2021 was $4.78M, representing a decrease of -7.45% compared to 2020.
What is China SXT Pharmaceuticals’s quarterly revenue?
China SXT Pharmaceuticals's quarterly revenue for Q2 2024 was $939.58K, a 100.00% increase from the previous quarter (Q1 2024), and a -22.24% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $469.79K, a -38.46% decrease from the previous quarter (Q4 2023), and a -22.24% decrease year-over-year (Q1 2023). SXTC's quarterly revenue for Q4 2023 was $763.39K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is China SXT Pharmaceuticals’s revenue growth rate?
China SXT Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -58.73%, and for the last 5 years (2019-2023) was -71.88%.